Associated Papers
CALR-mutant myeloproliferative neoplasms: insights from next-generation sequencing.
Mroczkowska-Bękarciak A et al.
Journal of Applied Genetics, 2026
Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease.
von Scheidt M et al.
European Heart Journal, 2026
40900105 (PubMed )
Supplement: ehaf602_supplementary_data.pdf
A framework for the molecular identification of CHIP for clinical research.
Harraka P et al.
Hgg Advances, 2026
41566785 (PubMed )
Supplement: mmc2.xlsx › Sheet1
Clonal hematopoiesis associates with prevalent and incident cardiometabolic disease in a cardiac catheterization cohort.
Regan JA et al.
Plos One, 2026
41666166 (PubMed )
Supplement: pone.0339491.s009.xlsx › S4_Table
Ancestry-dependent patterns of somatic mosaicism and clonal hematopoiesis mutations in over 125,000 individuals reveal distinct cancer associations.
Colin-Leitzinger C et al.
Human Genomics, 2025
41331781 (PubMed )
Supplement: 40246_2025_847_MOESM1_ESM.pdf
Diagnostic relevance of SH2B3 mutations in suspected myeloid malignancies and acute leukemia: insights from a large-scale NGS-based screening study.
Ben Dhia L et al.
Blood Cancer Journal, 2025
41136376 (PubMed )
Supplement: 41408_2025_1392_MOESM2_ESM.pdf
Clonal haematopoiesis associates with distinct cytometric changes of red blood cells and platelets.
Salzbrunn JB et al.
British Journal of Haematology, 2025
40754673 (PubMed )
Supplement: BJH-207-1085-s002.xlsx › CH_cohort
Integrating Molecular Alterations with Immunophenotype and Clinical Characteristics in Myelodysplastic Syndromes: A Single-Center Study.
Majcherek M et al.
International Journal of Molecular Sciences, 2025
40806511 (PubMed )
Supplement: ijms-26-07382-s001.zip › ijms-3714525-supplementary.pdf
Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project.
Kato T et al.
British Journal of Cancer, 2025
40325148 (PubMed )
Supplement: 41416_2025_2985_MOESM2_ESM.xlsx › Supplementary_Table_S2
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
Ikoma Y et al.
Leukemia, 2025
40259101 (PubMed )
Supplement: 41375_2025_2625_MOESM2_ESM.xlsx › Sheet5
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.
Hiitola E et al.
Science Advances, 2025
40305610 (PubMed )
Supplement: sciadv.adt9846_tables_s1_to_s13.zip › adt9846_tables_s1_to_s13.xlsx › S3
Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype.
Rondoni M et al.
Cancers, 2025
40227798 (PubMed )
Supplement: cancers-17-01213-s001.zip › cancers-3416916-supplementary.pdf
Double mutant DNMT3A AML: a unique subtype experiencing increased DNA damage and poor prognosis.
Boertjes EL et al.
Blood Advances, 2025
39693514 (PubMed )
Supplement: BLOODA_ADV-2024-014698-mmc1.pdf
Relationship between additional mutations at diagnosis and treatment response in patients with essential thrombocythemia.
Mosnier C et al.
Blood Advances, 2025
39820709 (PubMed )
Supplement: BLOODA_ADV-2024-014791-mmc1.pdf
Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study.
Guerineau H et al.
American Journal of Hematology, 2025
39654506 (PubMed )
Supplement: supplement_1.pdf
Comparative analysis of the Mexico City Prospective Study and the UK Biobank identifies ancestry-specific effects on clonal hematopoiesis.
Wen S et al.
Nature Genetics, 2025
39948438 (PubMed )
Supplement: 41588_2025_2085_MOESM4_ESM.xlsx › ST_5
cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem Cell Transplantation for Myeloid Malignancies.
Rowley SD et al.
Cancers, 2025
40002220 (PubMed )
Supplement: cancers-17-00625-s001.zip › cancers-3405985-supplementary.pdf
Clonal Hematopoiesis Associates with Prevalent and Incident Cardiometabolic Disease in High-Risk Individuals.
Regan JA et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
39867361 (PubMed )
Supplement: media-1.xlsx › Supplemental_Table_4
Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.
Kindt CK et al.
International Journal of Cancer, 2024
39128978 (PubMed )
Supplement: supplement_1.pdf
Impact of cytotoxic therapy on clonal hematopoiesis and myeloid neoplasms in breast cancer patients.
Kim H et al.
Medicine, 2024
39560556 (PubMed )
Supplement: medi-103-e40540-s001.xlsx › Table_S1
Risk prediction for clonal cytopenia: multicenter real-world evidence.
Xie Z et al.
Blood, 2024
38996210 (PubMed )
Supplement: BLOOD_BLD-2024-024756-mmc1.pdf
Unidirectional association of clonal hematopoiesis with atherosclerosis development.
Díez-Díez M et al.
Nature Medicine, 2024
39215150 (PubMed )
Supplement: 41591_2024_3213_MOESM3_ESM.xlsx › Supplementary_Table_2
Landscape of biallelic DNMT3A mutant myeloid neoplasms.
Kawashima N et al.
Journal of Hematology & Oncology, 2024
39334207 (PubMed )
Supplement: 13045_2024_1607_MOESM2_ESM.xlsx › Table_S8
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.
Jakobsen NA et al.
Cell Stem Cell, 2024
38917807 (PubMed )
Supplement: mmc3.xlsx › Table_S2b
Association Between Clonal Hematopoiesis and Left Ventricular Reverse Remodeling in Nonischemic Dilated Cardiomyopathy.
Inoue S et al.
Jacc. Basic to Translational Science, 2024
39297129 (PubMed )
Supplement: mmc1.pdf
Multiomic profiling of human clonal hematopoiesis reveals genotype and cell-specific inflammatory pathway activation.
Heimlich JB et al.
Blood Advances, 2024
38507736 (PubMed )
Supplement: BLOODA_ADV-2023-011445-mmc1.pdf
Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.
Chen SH et al.
Cancer Medicine, 2024
38895905 (PubMed )
Supplement: CAM4-13-e7384-s003.xlsx › Sheet1
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
Vanni I et al.
Journal of Translational Medicine, 2024
38750555 (PubMed )
Supplement: 12967_2024_5227_MOESM15_ESM.xlsx › S15
Clonal hematopoiesis is associated with cardiovascular events in patients with stable coronary artery disease.
Dregoesc MI et al.
Iscience, 2024
38558938 (PubMed )
Supplement: mmc4.xlsx › Variant_characteristics
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
39516321 (PubMed )
Supplement: 44276_2024_49_MOESM4_ESM.xlsx › supplementary_table_2
Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues-Brief Report.
Dederichs TS et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2024
38269586 (PubMed )
Supplement: atv-44-690-s001.pdf
Clonal hematopoiesis with DNMT3A and PPM1D mutations impairs regeneration in autologous stem cell transplant recipients.
Stelmach P et al.
Haematologica, 2023
37381752 (PubMed )
Supplement: 2023_282992_STELMACH_SUPPL.pdf
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y et al.
Molecular Oncology, 2023
37584393 (PubMed )
Supplement: MOL2-17-2183-s002.xlsx › Table_S3
Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis.
Uddin MM et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
37732181 (PubMed )
Supplement: media-2.xlsx › Table_S3
Leukocytes carrying Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations invade Human Atherosclerotic Plaques.
von Scheidt M et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
37546840 (PubMed )
Supplement: media-1.pdf
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Nannya Y et al.
Blood Advances, 2023
36989067 (PubMed )
Supplement: BLOODA_ADV-2022-009564-mmc2.xlsx › SuppTable3
Recurrent missense variants in clonal hematopoiesis-related genes present in the general population.
Ariste O et al.
Clinical Genetics, 2023
Compartment-specific mutational landscape of clonal hematopoiesis.
Hartmann L et al.
Leukemia, 2022
36131041 (PubMed )
Supplement: 41375_2022_1700_MOESM1_ESM.pdf
Cancer-driving mutations are enriched in genic regions intolerant to germline variation.
Vitsios D et al.
Science Advances, 2022
36026442 (PubMed )
Supplement: sciadv.abo6371_tables_s1_to_s13.zip › sciadv.abo6371_tables_s1_to_s13.xlsx › S4
Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts.
Brojakowska A et al.
Communications Biology, 2022
Utility of plasma cell-free DNA for de novo detection and quantification of clonal hematopoiesis.
Gutierrez-Rodrigues F et al.
Haematologica, 2022
34587721 (PubMed )
Supplement: 2021_279230_GUTIERREZ-RODRIGUES_SUPPL.pdf
Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases.
Cheng X et al.
Current Opinion in Structural Biology, 2022
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Liu B et al.
Cancer Medicine, 2022
35393784 (PubMed )
Supplement: CAM4-11-2767-s001.xlsx › Table_S2
1–50 of 83 papers
Select a paper to view details